Arrowhead to Report Fiscal 2015 Second Quarter Financial Results
May 04 2015 - 4:01PM
Business Wire
Conference Call Scheduled for Monday, May 11,
2015
Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that it will report its financial results for the
fiscal 2015 second quarter ended March 31, 2015, on Monday, May 11,
2015, at 4:30 p.m. EST. To participate in the conference call,
please dial 855-215-6159 (toll free from the US) or 315-625-6887
(for international callers) and enter Conference ID 40592020.
Investors may also access a live audio webcast of this conference
call on the Company's website at
http://ir.arrowheadresearch.com/events.cfm.
A replay of the webcast will be available approximately two
hours after the conclusion of the call and will remain available
for 90 days. An audio replay will also be available approximately
two hours after the conclusion of the call and will be available
for 7 days. The audio replay can be accessed by dialing
855-859-2056 (toll free from the US), or 404-537-3406 (for
international callers) and entering Conference ID 40592020.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate™ delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver
disease associated with Alpha-1 antitrypsin deficiency.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, actions of the U.S. Food
and Drug Administration (FDA) and similar global regulatory bodies,
rapid technological change in our markets, and the enforcement of
our intellectual property rights. Arrowhead Research Corporation's
most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q discuss some of the important risk factors
that may affect our business, results of operations and financial
condition. We assume no obligation to update or revise
forward-looking statements to reflect new events or
circumstances.
Source: Arrowhead Research Corporation
Arrowhead Research CorporationVince Anzalone, CFA,
626-304-3400ir@arrowres.comorInvestor Relations:The Trout GroupTodd
James, 646-378-2926ir@arrowres.comorMedia:Russo PartnersMatt
Middleman, M.D.,
212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024